Begrænsning af den dosis, der injiceres i musculus sternocleidomastoideus, til mindre end 100 E kan eventuelt reducere forekomsten af synkebesvær.
Limiting the dose injected into the sternocleidomastoid muscle to less than 100 U may decrease the occurrence of dysphagia.